Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A conventional osteosarcoma characterized by the predominance of osteoid matrix.
Biomarker and diagnostic research for osteoblastic osteosarcoma has been reported in the published literature.
106 clinical trials registered, 62 recruiting. Interventions under study include drug therapy, other interventions, procedural interventions, and biologic therapy. Pipeline includes 1 PHASE4, 4 PHASE3, 28 PHASE2. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT03458520](https://clinicaltrials.gov/study/NCT03458520) |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 12:48 AM UTC
Pediatric PET/MR Image Registry |
— |
Stanford University |
RECRUITING |
[NCT06064682](https://clinicaltrials.gov/study/NCT06064682) | An Organoid-based Functional Precision Medicine Trial in Osteosarcoma | — | Jonsson Comprehensive Cancer Center | RECRUITING |
[NCT03721068](https://clinicaltrials.gov/study/NCT03721068) | Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma | PHASE1 | UNC Lineberger Comprehensive Cancer Center | RECRUITING |
[NCT06650514](https://clinicaltrials.gov/study/NCT06650514) | A Phase 2 Pilot Study to Evaluate the Safety and the Anti-Tumour Activity of the Myc Inhibitor OMO-103 Administered Intravenously in Patients With Advanced High-Grade Osteosarcoma | PHASE2 | Vall d'Hebron Institute of Oncology | RECRUITING |
[NCT06492954](https://clinicaltrials.gov/study/NCT06492954) | Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma | PHASE1 | Emory University | RECRUITING |
18 publications have been identified in PubMed for osteoblastic osteosarcoma. Research spans Case Report / Case Series (44%), Epidemiology / Natural History (17%), and Review / Meta-Analysis (11%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 8 | 44% |
Disease patterns and progression | 3 | 17% |
Research summaries | 2 | 11% |
Laboratory research | 2 | 11% |
Other research | 1 | 6% |
Testing and diagnosis research | 1 | 6% |
New treatment approaches | 1 | 6% |
Maccagnan F (2026). [PMID: 41794779](https://pubmed.ncbi.nlm.nih.gov/41794779/). *BMC Vet Res*. [Case Report / Case Series]
Lefeuvre G (2025). [PMID: 40510275](https://pubmed.ncbi.nlm.nih.gov/40510275/). *Can Vet J*. [Case Report / Case Series]
Ivan A (2025). [PMID: 39941196](https://pubmed.ncbi.nlm.nih.gov/39941196/). *Diagnostics (Basel)*. [Epidemiology / Natural History]
Miyagi H (2025). [PMID: 41318771](https://pubmed.ncbi.nlm.nih.gov/41318771/). *Sci Rep*. [Diagnostic / Biomarker]
Wert E (2025). [PMID: 41560724](https://pubmed.ncbi.nlm.nih.gov/41560724/). *Front Pharmacol*. [Case Report / Case Series]
Khalil Y (2025). [PMID: 40062377](https://pubmed.ncbi.nlm.nih.gov/40062377/). *Otol Neurotol*. [Review / Meta-Analysis]
Power K (2025). [PMID: 40196812](https://pubmed.ncbi.nlm.nih.gov/40196812/). *Front Vet Sci*. [Gene Therapy / Novel Therapeutics]
Lee-Diaz E (2025). [PMID: 39177043](https://pubmed.ncbi.nlm.nih.gov/39177043/). *J Cutan Pathol*. [Other]
Mahdal M (2025). [PMID: 39574804](https://pubmed.ncbi.nlm.nih.gov/39574804/). *Oncol Lett*. [Case Report / Case Series]
Rossi F (2025). [PMID: 40318747](https://pubmed.ncbi.nlm.nih.gov/40318747/). *Acta Biomater*. [Basic Science / Preclinical]